GlaxoSmithKline plc said GSK2857916 showed positive results in previously treated multiple myeloma patients enrolled in the phase 1/2 DREAMM-1 study.
Multiple myeloma is a bone marrow cancer that affects plasma cells.
The study showed that 60% of the patients responded to GSK2857916 which targets the BCMA protein, responsible for promoting plasma cell survival.
The drug also demonstrated a progression-free survival of 7.9 months, a measure of how long a patient lived before the disease worsening.
More than half of the patients enrolled in the study had undergone five previous lines of therapies. A portion of the patients were previously treated with Johnson & Johnson's Darzalex or daratumumab.
The drug was previously awarded the breakthrough therapy designation from the U.S. Food and Drug Administration and prime designation from the European Medicines Agency.
